KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Low-Dose TEL/AML/CHTD SPC Versus Standard-Dose TEL in Hypertension: Phase III RCT.

Jeong Cheon Ahn, Cheol Whan Lee, Jong-Hwa Ahn, Kyung Hee Lim, Il Suk Sohn, Ki-Chul Sung, Kye Hun Kim, Jang-Ho Bae, Seung Pyo Hong, Won-Young Jang, Sang-Ho Jo, Seung Hwan Han, Ji Bak Kim, Chan Joo Lee, Ju-Hee Lee, Namkyun Kim, Eun Joo Cho, Jung-Hoon Sung, Hyo-Suk Ahn, Seok-Yeon Kim, Jinho Shin, Suk Min Seo, Soon Jun Hong, Weon Kim, Chang-Gyu Park

Hypertension 83(4) e25810

PMID41717679
PMCIDPMC13001893
DOI10.1161/HYPERTENSIONAHA.125.25810
发表日期2026-02-20
入排依据:未发现恶性肿瘤人群证据。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:Figure 1.:图注未提示 KM 曲线;Figure 2.:图注未提示 KM 曲线;Figure 3.:森林图/亚组分析图。
摘要

摘要

BACKGROUND: Although low-dose triple single-pill combination therapies show promising efficacy and safety, studies comparing them to standard-dose monotherapies remain limited. This phase III, randomized, double-blind trial evaluated the efficacy and safety of a low-dose single-pill combination of telmisartan, amlodipine, and chlorthalidone versus standard-dose telmisartan monotherapy in patients with essential hypertension. METHODS: After a 4-week placebo run-in period, 314 eligible subjects were randomized to either receive telmisartan/amlodipine/chlorthalidone 20/2.5/6.25 mg or telmisartan 40 mg for 8 weeks. The primary efficacy end point was the change in mean sitting systolic blood pressure from baseline to week 8, with noninferiority assessed in the per-protocol set (PPS), followed by superiority testing in the full analysis set using a gatekeeping approach to control for type I error. RESULTS: At week 8, the combination group demonstrated significant mean sitting systolic blood pressure reduction compared with monotherapy in the per-protocol set analysis (least squares mean difference, -3.8 mm Hg [95% CI: -6.7 to -0.9]; P=0.01), establishing its noninferiority. Furthermore, the superiority of the combination therapy was confirmed in the full analysis set (LS mean difference, -4.0 mm Hg [95% CI, -6.8 to -1.3]; P<0.01). Mean sitting diastolic BP, BP normalization rates, and response rates also favored the combination group at weeks 4 and 8 (all P<0.01). Subgroup analyses showed consistent efficacy across clinical strata, including age and prior antihypertensive treatment. The incidence of adverse events was comparable between groups, with no serious drug-related events reported. CONCLUSIONS: Low-dose triple single-pill combination of telmisartan/amlodipine/chlorthalidone demonstrated superior BP-lowering efficacy with well-tolerated and comparable safety to standard-dose telmisartan monotherapy. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT06348576.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1.Subject disposition throughout the study. Primary reasons for discontinuation included: (1) withdrawal of consent; (2) use of prohibited concurrent medication; (3) noncompliance with the investigator’s instructions; (4) failure to meet selection criteria; (5) inability to continue study participation due to adverse events; (6) excessive elevation or decrease in blood pressure observed during a scheduled (visit 3) or unscheduled visit; (7) pregnancy during treatment period; (8) loss of follow-up; (9) other reasons as determined by the investigator to warrant discontinuation of the study. AML indicates amlodipine, CHTD, chlorthalidone, N, number of subjects; and TEL, telmisartan.
非 KM Figure
Figure 2.Change in mean sitting systolic blood pressure from baseline to week 4 and week 8 (full analysis set). Data are presented as least squares (LS) mean differences between treatment groups at each visit, estimated using an ANCOVA model with baseline mean sitting systolic blood pressure (MSSBP) as a covariate. Values in brackets indicate 95% CIs for the LS mean differences. AML indicates amlodipine, CHTD, chlorthalidone, and TEL, telmisartan. * P <0.05; ** P <0.01.
非 KM Figure
Figure 3.Subgroup analysis of least squares mean change in mean sitting systolic blood pressure (BP) at week 8 based on interaction models (full analysis set). Forest plot depicting least squares (LS) mean changes in mean sitting systolic BP (MSSBP) at week 8 comparing telmisartan (TEL)/amlodipine (AML)/chlorthalidone (CHTD) 20/2.5/6.25 mg vs TEL 40 mg across key subgroups: baseline systolic BP (<160 vs ≥160 mm Hg), prior antihypertensive treatment (yes vs no), age (<60 vs ≥60 years), and duration of hypertension (<5 vs ≥5 years). The LS mean differences were estimated from ANCOVA models including baseline MSSBP, subgroup, treatment, and treatment-by-subgroup interaction as fixed effects. Each subgroup displays the LS mean difference with 95% CIs. Negative values favor the TEL/AML/CHTD combination. The treatment effect was consistent across most subgroups, with the largest reductions observed in patients with baseline systolic BP (SBP) ≥160 mm Hg and those aged ≥60 years. No statistically significant treatment-by-subgroup interactions were observed ( Table S4 ). N indicates number of subjects.
非 KM Figure